Julian D G
British Heart Foundation, London, England.
Clin Cardiol. 1990 Mar;Suppl 5:V20-1; discussion V27-32. doi: 10.1002/clc.4960131306.
The anistreplase (anisoylated plasminogen streptokinase activator complex or APSAC) intervention mortality study was designed as a double-blind, placebo-controlled study to test the effectiveness of anistreplase, 30 U administered intravenously within the first 6 hours of acute myocardial infarction. The primary endpoint of the study was mortality of all causes at 30 days and 1 year. Within 30 days, there were 77 deaths with placebo (17.8%) and 40 deaths (6.5%) with anistreplase, an odds reduction of 50.5% (p = 0.0006). By the end of one year, there had been a total of 113 deaths (17.8%) with placebo and 69 deaths (11.1%) with anistreplase, an odds reduction of 42.7% (p = 0.0007).
茴香酰化纤溶酶原链激酶激活剂复合物（APSAC）干预死亡率研究被设计为一项双盲、安慰剂对照研究，以测试在急性心肌梗死发病后6小时内静脉注射30单位茴香酰化纤溶酶原链激酶激活剂复合物（APSAC）的有效性。该研究的主要终点是30天和1年时的全因死亡率。30天内，安慰剂组有77例死亡（17.8%），茴香酰化纤溶酶原链激酶激活剂复合物（APSAC）组有40例死亡（6.5%），比值降低了50.5%（p = 0.0006）。到1年末，安慰剂组共有113例死亡（17.8%），茴香酰化纤溶酶原链激酶激活剂复合物（APSAC）组有69例死亡（11.1%），比值降低了42.7%（p = 0.0007）。
